Skip to product information
1 of 1

CLEC7A Recombinant Rabbit mAb (S-1043-136)

CLEC7A Recombinant Rabbit mAb (S-1043-136)

Catalog Number: S0B0911 Application: FCM Reactivity: Mouse Conjugation: Unconjugated Brand: Starter
Price:
Regular price $130.00 SGD
Regular price Sale price $130.00 SGD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Antigen CLEC7A
Synonyms C-type lectin domain family 7 member A, Beta-glucan receptor, C-type lectin superfamily member 12, Dendritic cell-associated C-type lectin 1 (DC-associated C-type lectin 1; Dectin-1), CD369, Bgr, Clecsf12, Dectin1
Immunogen Recombinant Protein
Location Cell membrane
Accession Q6QLQ4
Clone Number S-1043-136
Antibody Type Recombinant mAb
Isotype IgG
Application FCM
Reactivity Ms
Purification Protein A
Concentration 0.5 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300
Stability & Storage

12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution


application dilution species
FCM 1:50 null

Background

CLEC7A, also known as Dectin-1, is a type of C-type lectin receptor that is predominantly expressed on immune cells such as macrophages, dendritic cells, and neutrophils. Its primary function is to recognize pathogen-associated molecular patterns (PAMPs), such as fungal β-glucans, triggering immune responses. Upon binding to PAMPs, CLEC7A activates downstream signaling pathways that lead to the production of inflammatory cytokines and the activation of immune cells, which work together to clear pathogens and protect the body from infection. In addition to its role in pathogen recognition and clearance, CLEC7A is also involved in cell adhesion and migration, which are important for cell interactions, signal transduction, and tissue organization. Moreover, recent research has highlighted the role of CLEC7A in neurological conditions. A study published in Advanced Science suggests that CLEC7A plays a critical role in ischemic stroke by exacerbating microglia-mediated synapse elimination, indicating that it may be a potential therapeutic target for stroke treatment. Furthermore, research has shown that CLEC7A, along with TREM2, another immune receptor on microglia, can activate spleen tyrosine kinase (SYK), which is crucial for the activation of microglia into disease-associated microglia (DAM) that clear amyloid-beta (Aβ) plaques in Alzheimer's disease (AD).

Picture

FC

Flow cytometric analysis of Neuro-2a (Mouse neuroblastoma neuroblast, left) / K562 (Human chronic myelogenous leukemia lymphoblast, right) labelling CLEC7A antibody at 1/50 dilution (1 μg) / (Red) compared with a Rabbit monoclonal IgG (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). Goat Anti - Mouse IgG Alexa Fluor® 488 was used as the secondary antibody.
Negative control: Neuro-2a

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)